The evolutionary path of our CorPath® GRX is approaching several major milestones in 2022 that mark the next steps in our mission to revolutionize interventional treatment and expand access to care. The demand for innovative and transformative technology has never been greater and we are poised to meet the market’s demand for innovation.
As we close 2021 and look ahead to the new year, these are some of the projects that will reshape our technology in 2022:
Remote Robotic Treatment
In 2022, we plan to initiate a first-of-its-kind trial to gather clinical evidence on the procedural success and technical performance of remote robotic-assisted percutaneous coronary intervention treatment. By evolving our understanding of telehealth – a predominantly diagnostic tool today – to a modality that can deliver life-saving interventional treatment to patients remotely, we strive to improve workflow efficiency and expand access to care for patients.
When Dr. Tejas Patel successfully completed the world’s first remote coronary procedures on five patients in 2018, it proved the viability of remote-operated robotics for cardiovascular intervention. His revolutionary work validated the concept of remote “mesh networks” among health systems – meaning a physician at one location in a hospital network can treat a patient with an emergent condition who presents at any other location with robotic assistance.
One year later, Dr. Ryan Madder completed the first ever simulated transcontinental test coronary interventions in the U.S. using CorPath GRX connected through a variety of networks, including 5G wireless, dedicated fiber and commercial public internet.
CorPath GRX’s precision has made the technology enticing to neurovascular interventionalists who perform procedures in extremely small and tortuous anatomy. The nature of vessels in the brain presents unique challenges that may benefit from our system’s ability to drive medical devices in submillimeter increments and deliver therapy with enhanced control.
In 2019, Dr. Vitor Mendes Pereira performed the first in-human, robotic-assisted neurovascular intervention with CorPath GRX and validated the platform’s capability in another part of the body. Now we are expanding CorPath GRX’s indication in neurovascular care, with the goal to deliver precision medicine in an extremely delicate part of the body that has a dire need for enhanced treatment options: the brain. CorPath GRX already received CE Mark for neurovascular procedures, and a clinical trial in Europe is underway to support robotic-assisted aneurysm treatment with the platform in other areas of the world.
Expanding our indication into neurovascular care comes with enhancements to the existing robotic system as the devices used for an aneurysm procedure are different than the ones used in cardiovascular treatment. For instance, the catheters and wires for an aneurysm procedure are longer than the ones used for PCI.
New headquarters to support growth, R&D
In addition to advances to our technology, Corindus is moving its headquarters to a new Siemens Healthineers facility in Newton, Mass., which is more than double the size of our current facility. The new space will house office space, R&D and manufacturing, allowing us to support future growth, dramatically increase our production capacity, and enhance the work environment for employees. A larger R&D lab will fuel innovation, and the space will include a state-of-the-art Customer Experience Center.
Both the new facility and our advances in remote treatment and neurovascular care are aimed at supporting a paradigm-altering technology that has potential to impact population health in the future. We expect a year of meaningful milestones in 2022 and look forward to answering market demand for technology innovation.